Neruban Kumaran1,2, Gary S Rubin1,2, Angelos Kalitzeos1,2, Kaoru Fujinami1,2,3,4, James W B Bainbridge1,2, Richard G Weleber5, Michel Michaelides1,2. 1. UCL Institute of Ophthalmology, University College London, London, United Kingdom. 2. Moorfields Eye Hospital, London, United Kingdom. 3. National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan. 4. Keio University, School of Medicine, Tokyo, Japan. 5. Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.
Abstract
Purpose: RPE65-associated Leber congenital amaurosis (RPE65-LCA) is an early-onset severe retinal dystrophy associated with progressive visual field loss. Phase I/II and III gene therapy trials have identified improved retinal sensitivity but little is known about the natural history of retinal sensitivity in RPE65-LCA. Methods: A total of 19 subjects (aged 9 to 23 years) undertook monocular full-field static perimetry of which 13 subjects were monitored longitudinally. Retinal sensitivity was measured as mean sensitivity (MS) and volumetrically quantified (in decibel-steradian) using visual field modeling and analysis software for the total (VTOT), central 30° (V30) and central 15° (V15) visual field. Correlation was evaluated between retinal sensitivity and age, best-corrected visual acuity (BCVA), contrast sensitivity, vision-related quality of life, and genotype. Test-retest reliability was also investigated. Results: V30 was identified to have a strong, weak, and moderate correlation with age, BCVA and contrast sensitivity respectively. Furthermore, V30 was identified as having a weak linear relationship with the mobility and independence domains of the vision-related quality of life questionnaire. Longitudinal analysis demonstrated a slow loss of retinal sensitivity in this cohort. Subjects with at least one RPE65 nonsense variant appeared to show greater progressive loss of retinal sensitivity in the second decade of life than those without. Conclusions: Volumetric assessment of central 30° visual field sensitivity, V30, is a useful independent measure of retinal function and, in our data, represented the best metric to monitor deterioration of retinal sensitivity in RPE65-LCA. Furthermore, functional correlation with genotype may enable more informed prognostic counseling. (ClinicalTrials.gov number, NCT02714816.)
Purpose: RPE65-associated Leber congenital amaurosis (RPE65-LCA) is an early-onset severe retinal dystrophy associated with progressive visual field loss. Phase I/II and III gene therapy trials have identified improved retinal sensitivity but little is known about the natural history of retinal sensitivity in RPE65-LCA. Methods: A total of 19 subjects (aged 9 to 23 years) undertook monocular full-field static perimetry of which 13 subjects were monitored longitudinally. Retinal sensitivity was measured as mean sensitivity (MS) and volumetrically quantified (in decibel-steradian) using visual field modeling and analysis software for the total (VTOT), central 30° (V30) and central 15° (V15) visual field. Correlation was evaluated between retinal sensitivity and age, best-corrected visual acuity (BCVA), contrast sensitivity, vision-related quality of life, and genotype. Test-retest reliability was also investigated. Results: V30 was identified to have a strong, weak, and moderate correlation with age, BCVA and contrast sensitivity respectively. Furthermore, V30 was identified as having a weak linear relationship with the mobility and independence domains of the vision-related quality of life questionnaire. Longitudinal analysis demonstrated a slow loss of retinal sensitivity in this cohort. Subjects with at least one RPE65 nonsense variant appeared to show greater progressive loss of retinal sensitivity in the second decade of life than those without. Conclusions: Volumetric assessment of central 30° visual field sensitivity, V30, is a useful independent measure of retinal function and, in our data, represented the best metric to monitor deterioration of retinal sensitivity in RPE65-LCA. Furthermore, functional correlation with genotype may enable more informed prognostic counseling. (ClinicalTrials.gov number, NCT02714816.)
Authors: B Lorenz; P Gyürüs; M Preising; D Bremser; S Gu; M Andrassi; C Gerth; A Gal Journal: Invest Ophthalmol Vis Sci Date: 2000-08 Impact factor: 4.799
Authors: Ecosse L Lamoureux; Julie F Pallant; Konrad Pesudovs; Gwyn Rees; Jennifer B Hassell; Jill E Keeffe Journal: Invest Ophthalmol Vis Sci Date: 2007-03 Impact factor: 4.799
Authors: Samuel G Jacobson; Tomas S Aleman; Artur V Cideciyan; Alejandro J Roman; Alexander Sumaroka; Elizabeth A M Windsor; Sharon B Schwartz; Elise Heon; Edwin M Stone Journal: Invest Ophthalmol Vis Sci Date: 2008-12-30 Impact factor: 4.799
Authors: Richard G Weleber; Travis B Smith; Dawn Peters; Elvira N Chegarnov; Scott P Gillespie; Peter J Francis; Stuart K Gardiner; Jens Paetzold; Janko Dietzsch; Ulrich Schiefer; Chris A Johnson Journal: Transl Vis Sci Technol Date: 2015-04-28 Impact factor: 3.283
Authors: A R Philp; M Jin; S Li; E I Schindler; A Iannaccone; B L Lam; R G Weleber; G A Fishman; S G Jacobson; R F Mullins; Gabriel H Travis; Edwin M Stone Journal: Hum Mutat Date: 2009-08 Impact factor: 4.878
Authors: Thomas M W Buckley; Amandeep Singh Josan; Laura J Taylor; Jasleen K Jolly; Jasmina Cehajic-Kapetanovic; Robert E MacLaren Journal: Transl Vis Sci Technol Date: 2022-05-02 Impact factor: 3.048
Authors: Neruban Kumaran; Michalis Georgiou; James W B Bainbridge; Mette Bertelsen; Michael Larsen; Fiona Blanco-Kelly; Carmen Ayuso; Hoai Viet Tran; Francis L Munier; Angelos Kalitzeos; Michel Michaelides Journal: Invest Ophthalmol Vis Sci Date: 2020-04-09 Impact factor: 4.799
Authors: Anna Skorczyk-Werner; Zuzanna Niedziela; Marcin Stopa; Maciej Robert Krawczyński Journal: Orphanet J Rare Dis Date: 2020-12-11 Impact factor: 4.123
Authors: Neruban Kumaran; Robin R Ali; Nick A Tyler; James W B Bainbridge; Michel Michaelides; Gary S Rubin Journal: Transl Vis Sci Technol Date: 2020-09-03 Impact factor: 3.283
Authors: Michalis Georgiou; Navjit Singh; Thomas Kane; Serena Zaman; Nashila Hirji; Jonathan Aboshiha; Neruban Kumaran; Angelos Kalitzeos; Joseph Carroll; Richard G Weleber; Michel Michaelides Journal: Invest Ophthalmol Vis Sci Date: 2020-09-01 Impact factor: 4.925
Authors: Evgenia Anikina; Michalis Georgiou; James Tee; Andrew R Webster; Richard G Weleber; Michel Michaelides Journal: Am J Ophthalmol Date: 2021-07-22 Impact factor: 5.258